← Back to Screener
VYNE Therapeutics Inc. Common Stock (VYNE)
Price$0.63
Favorite Metrics
Price vs S&P 500 (26W)56.14%
Price vs S&P 500 (4W)-12.65%
Market Capitalization$20.33M
All Metrics
Book Value / Share (Quarterly)$0.83
P/TBV (Annual)1.78x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.90%
Cash Flow / Share (Quarterly)$-0.99
Price vs S&P 500 (YTD)1.03%
Gross Margin (TTM)81.03%
Net Profit Margin (TTM)-4646.14%
EPS (TTM)$-0.62
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-0.62
Revenue Growth (5Y)-51.38%
EPS (Annual)$-0.62
ROI (Annual)-95.38%
Gross Margin (Annual)93.38%
Net Profit Margin (5Y Avg)-6405.56%
Cash / Share (Quarterly)$0.72
Revenue Growth QoQ (YoY)54.76%
ROA (Last FY)-87.81%
Revenue Growth TTM (YoY)13.77%
EBITD / Share (TTM)$-0.62
ROE (5Y Avg)-85.74%
Operating Margin (TTM)-5219.30%
Cash Flow / Share (Annual)$-0.99
P/B Ratio0.73x
P/B Ratio (Quarterly)0.70x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)-6.49x
Net Interest Coverage (TTM)-6.96x
ROA (TTM)-63.27%
EPS Incl Extra (Annual)$-0.62
Current Ratio (Annual)12.53x
Quick Ratio (Quarterly)12.11x
3-Month Avg Trading Volume3.58M
52-Week Price Return-66.20%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.48
P/S Ratio (Annual)35.67x
Asset Turnover (Annual)0.02x
52-Week High$1.99
Operating Margin (5Y Avg)-6431.85%
EPS Excl Extra (Annual)$-0.62
CapEx CAGR (5Y)63.54%
Tangible BV CAGR (5Y)-9.69%
26-Week Price Return64.89%
Quick Ratio (Annual)12.11x
13-Week Price Return7.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.53x
Enterprise Value$-3.697
Revenue / Share Growth (5Y)-74.21%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-44.36%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4689.82%
Cash / Share (Annual)$0.72
3-Month Return Std Dev29.76%
Net Income / Employee (TTM)$-3
ROE (Last FY)-95.38%
Net Interest Coverage (Annual)-8.77x
EPS Basic Excl Extra (Annual)$-0.62
Receivables Turnover (TTM)0.90x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.62
Receivables Turnover (Annual)0.12x
ROI (TTM)-74.15%
P/S Ratio (TTM)35.67x
Pretax Margin (5Y Avg)-6215.80%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$9.73
Price vs S&P 500 (52W)-101.29%
Year-to-Date Return5.17%
5-Day Price Return-2.35%
EPS Normalized (Annual)$-0.62
ROA (5Y Avg)-68.56%
Net Profit Margin (Annual)-4646.14%
Month-to-Date Return2.11%
Cash Flow / Share (TTM)$-9.09
EBITD / Share (Annual)$-0.62
Operating Margin (Annual)-5219.12%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-85.74%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.62
P/TBV (Quarterly)4.86x
P/B Ratio (Annual)0.70x
Inventory Turnover (TTM)0.21x
Pretax Margin (TTM)-4689.82%
Book Value / Share (Annual)$0.83
Price vs S&P 500 (13W)4.81%
Beta2.01x
Revenue / Share (TTM)$0.01
ROE (TTM)-74.15%
52-Week Low$0.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.90
3.90
3.90
3.90
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VYNEVYNE Therapeutics Inc. Common Stock | 35.67x | 13.77% | 81.03% | — | $0.63 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
VYNE Therapeutics is a biopharmaceutical company developing therapies for immuno-inflammatory skin conditions. The company markets dermatology products AMZEEQ and ZILXI while advancing FMX114 as its lead pipeline candidate for atopic dermatitis treatment. VYNE also maintains pre-clinical programs targeting BET inhibitors for potential future applications.